Furmonertinib Mesylate Tablets is a third-generation EGFR-TKI inhibitor, primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) with specific gene mutations. Its price is subject to factors such as specification, region and medical insurance policies, with the cost per box typically ranging from 500 to 800 US dollars (based on the specifications of 40mg/28 tablets or 80mg/28 tablets). The exact cost shall be calculated in accordance with the prescribed dosage; for instance, for a daily dosage of 160mg, the monthly treatment cost is approximately 1,590 US dollars.
Key Factors Influencing the Price
1. Drug Specifications
The 40mg/28 tablets specification is more affordable, but requires 2 tablets to be taken daily, amounting to 2 boxes per month on average.
The 80mg/28 tablets specification reduces the dosage required, yet has a higher per-box cost.
2. Medical Insurance and Reimbursement Policies
Furmonertinib has been included in the medical insurance catalogs of some provinces and municipalities, leading to a significant reduction in the out-of-pocket proportion after reimbursement.
3. Purchase Channels
Purchases from hospital pharmacies or designated drugstores are eligible for medical insurance reimbursement. Prices on some online platforms or overseas channels may fluctuate, and caution must be exercised against the risk of counterfeit drugs.
Precautions for Medication
Administer strictly as directed by a physician: Furmonertinib is a prescription drug and should only be taken after pathological testing confirms EGFR T790M mutation positivity. The dosage should not be adjusted nor the medication discontinued without medical advice.
Adverse reaction management:
Common side effects include diarrhea and skin rashes, which can be alleviated through dietary adjustments or local care.
In case of severe reactions such as interstitial lung disease and QT interval prolongation, discontinue the medication immediately and seek medical attention.
Regular rechecks: During the medication period, efficacy evaluation should be conducted every 2 to 3 months, and the disease status should be monitored through examinations such as CT scans and blood tests.
Guidance on Medical Consultation and Drug Purchase
It is recommended that patients take the drug under the guidance of oncologists or pulmonologists and purchase it through formal medical institutions. If facing significant economic pressure, patients may consult hospitals or public welfare organizations for special assistance programs. In addition, some provinces and municipalities have included targeted lung cancer therapy in the reimbursement scope for chronic and special diseases in outpatient services, which can further reduce the financial burden of medication.
